
Primary objectives

- **Dose escalation**: -Safety and tolerability of BT8009 as monotherapy and in combination with nivolumab or in patients having renal insufficiency. 
  -MTD and RP2D of BT8009 as monotherapy and in combination with nivolumab
- **Dose expansion**: -Clinical activity of BT8009 as monotherapy and in combination with nivolumab

Secondary objectives

- **Dose escalation**: -Preliminary signals of activity of BT8009 as monotherapy and in combination with nivolumab or in patients having renal insufficiency. 
  -PK parameters of BT8009 and MMAE 
  -Incidence of anti-drug antibody (ADA) development
- **Dose expansion**: -Safety and tolerability of BT8009 as monotherapy and in combination with nivolumab 
  -PK parameters of BT8009 and MMAE 
  -Incidence of ADA development

References


ESMO Abstract Number: 3716

For additional information, please contact Dr. McKean at mmckean@tnonc.com

Dr. McKean declares the following conflicts of interest

1. Meredith A. McKean, MD, MPH1,2; Johanna C. Bendell, MD1,2; Daniel P. Petrylak, MD3; Thomas Powles, MD4; Guru Sonpavde, MD5; Amy Dickson6; Lola Dosunmu, MD, MPH, MLA2; Melissa G. Hennessy4; Phil Jeffrey4; Michael Rigby4; Shawn Watson5; Terrence West5; Geoffrey Shapiro, MD, PhD1,5
2. Sarah Cannon Research Institute, Nashville, TN, USA; 3Tennessee Oncology, PLLC, Nashville, TN, USA; 4Yale Cancer Center, New Haven, CT, USA; 5Barts Cancer Institute, London, UK; 6Dana Farber Cancer Institute, Boston, MA, USA; 7Bicycle Therapeutics, Lexington, MA, USA; 8Sarah Cannon Development Innovations, Nashville, TN, USA; 9Bicycle Therapeutics, Cambridge, UK; 10Brigham and Women’s Hospital and Harvard Medical School, Boston, MA